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Impairment of olfaction is a characteristic and early feature of Parkinson’s disease. Recent data indicate that >95% of patients
with Parkinson’s disease present with signiﬁcantolfactory loss.Deﬁcits in the senseofsmell mayprecede clinicalmotorsymptoms
by years and can be used to assess the risk for developing Parkinson’s disease in otherwise asymptomatic individuals. This paper
summarizesthe availableinformationabout olfactoryfunctioninParkinson’sdisease,indicatingtheadvantageous useofolfactory
probes in early and diﬀerential diagnosis.
1.Prevalenceand Characterof
OlfactoryLossinPD
According to a recent study by Politis et al. [1], olfactory loss
belongs to the top-ﬁve most prevalent motor and nonmotor
symptoms in early stage PD patients that have aﬀected their
quality of life. Only pain is referred to as a more prevalent
troublesome nonmotor problem in this patient group.
In line with this result, virtually all studies performed
since the 1970s have shown olfactory disturbances in PD
patients. Published data on the prevalence of olfactory dys-
function in PD range from 45% and 49% in the pioneering
studies of Ansari and Johnson [2], and Ward et al. [3],
respectively, up to 74% in the work of Hawkes et al. [4],
or as high as 90% in a study published by Doty et al. [5].
In our recent multicentre study [6] using a comprehensive
testing method (see chapter 2) in a large sample of PD
patients (n = 400) from 3 independent populations, the
prevalence of olfactory dysfunction in people with PD was
greater than previously reported with regard to norms
obtained in healthy young subjects. More than 96% of PD
patients were found to present with olfactory dysfunction.
When using age-dependent normative criteria, 74.5% of
this study population was diagnosed with olfactory loss
(Figure 1). Furthermore, more than 80% ofPD patients with
smell loss were functionally anosmic or severely hyposmic
regardless of the olfactory test being used for diagnosis. Only
very few patients present with accompanying parosmia, or
phantosmia.
Ourdataalso conﬁrmed numerous previousstudieswith
regard to the lack of olfactory improvement after therapy
with dopaminergic agents [5, 7] and the missing correlation
between olfactory loss and both duration of disease [4, 5, 8]
and the clinical severity of PD as measured by means of
the Hoehn and Yahr scale and the UPDRS (compare [9])—
although some studies found a correlation between the
severity of PD and certain measures of olfactory function,
namely, latencies of olfactory event-related potentials [10]o r
results from an odor discrimination task [11]. With regard
to olfactory function, we did not ﬁnd major diﬀerences
between subtypes of PD, namely, tremor-dominant PD,
akinetic-rigid PD, and mixed-type PD. While this conﬁrms
previous observations in a small sample size of 37 patients
[7]( F i g u r e2), the present ﬁndings are in contrast to reports
by Stern and colleagues [8]w h or e p o r t e ds i g n i ﬁ c a n t l y
better odor identiﬁcation scores in patients with tremor-
p r e d o m i n a n tP Dt h a ni nc a s e sw i th postural instability-gait
disorder-predominant PD.Whilediﬀerencesbetweenstudies
may be due to the type of olfactory test used, sample size,
normative data, and age distribution (which varied between2 Parkinson’s Disease
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Figure 1: Olfactory function of the total number of 400 PD
patients. Results are shown as a composite TDI score (sum of
odor threshold, odor discrimination,and odor identiﬁcation score)
adjusted to age-related norms [6].
these investigations), available data allow the conclusion that
olfactory dysfunction is a highly reliable symptom of the
disease. This concurs with the results of a case-control study
on 90 PD patients and healthy controls by Bohnen et al. [12]
who found that the accuracy of smell testing in PD diagnosis
outweighstheaccuracyofmotortestbatteries,andalsoother
nonmotor tests of, for example, depression and anxiety.
2.TestingMethods
As the olfactory loss in PD has a general character, all three
olfactory qualities(threshold, discrimination, identiﬁcation)
are involved. Therefore, diﬀerent subtests of olfactory func-
tion may reﬂect smell loss in PD patients and may be used
as single measurement. Only a comprehensive approach,
however, allows a precise evaluation of olfactory function,
thatis,thatitwouldbebesttoperformall3subteststoobtain
a maximum of reliable information.
Psychophysical assessment of olfactory function is based
on the presentation of odors and the recording of the
subjects’ response. Advantage of this “low-tech” approach
include the speed of testing, allowing for rapid screening
of olfactory function [13, 14]. While screening tests only
diﬀerentiate between normal and pathologic states, more
extensive tests allow for a reliable discrimination between
anosmic, hyposmic, and normosmic subjects, respectively.
Good tests have to be based (1) on normative data acquired
and validated in (2) large samples (e.g., [15, 16]). Many
tests are based on a forced choice verbal identiﬁcation of
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Figure 2: Olfactory function in PD subtypes (TD: tremor-
dominant, AR: akinetic-rigid, e: equivalent type) and multiple
system atrophy (MSA) [7].
odors while others also include results from odor discrim-
ination and odor threshold measurements (comprehensive
approach; Figure 3).
Most tests are based on the identiﬁcation of odors.
In odor identiﬁcation tasks, an odorant is presented at a
suprathreshold concentration and subjects are required to
identifytheodorfromalistofdescriptors.Thisforced-choice
procedure controls the subjects’ response bias. A major
problem of odor identiﬁcation is, however, that it strongly
relies on the verbal abilities of the subject. Consequently, on
average,thisenablesfemalesubjectstooutperformmen[17].
In addition, odor identiﬁcation tests have a strong cultural
precondition as not all odors are known equally well in
various cultural groups.
The concept embedded in threshold tests is that a
subject is repeatedly exposed to ascending and descending
concentrations of the same odorant and is required to
identify the least detectable concentration for this individual
odor ([18]; see also [19]).
Other measures assessing olfactory loss may include
investigation of the patient’s quality of life, for example,
the “Questionnaire for Olfactory Dysfunction” [20], or the
recording of olfactory event-related potentials (for review,
see [21]).
In the near future, immunohistochemical, volumetric,
and functional neuroimaging studies of the olfactory sytem
might become relevant for PD diagnosis. There is still
little information about PD-speciﬁc changes of the olfactory
epithelium and their diagnostic use. In a recent study, weParkinson’s Disease 3
Figure3:“Sniﬃn’Sticks”testkitwhichiscomprisedof3individual
tests of olfactory function (phenyl ethyl alcohol odor threshold,
odor discrimination, and odor identiﬁcation). The scores of the
individual tests are summated to the so-called “TDI score” which
is a reliable means to estimate the degree of olfactory function.
compared bioptic material from PD patients for histolog-
ical/histochemical changes with that from patients with
olfactory dysfunction due to other reasons [22]. However,
we found no speciﬁc changes in the nasal mucosa of PD
patients. Further, it could be assumed that loss of olfactory
bulbvolumewouldbeareliableﬁndinginPDwhich,tosome
degree, might be helpful in diﬀerential and early diagnosis
of PD. Results from a recent study [23] indicated that there
is little if any diﬀerence in OB volume between PD patients
with anosmia/hyposmia and healthy, normosmic controls.
In another eﬀort to identify brain structures responsible for
smell loss in PD, functional magnetic resonance imaging
(fMRI) was used to investigate brain activity related to
olfactory processing in PD. Overall, the results of these
studies [24, 25] indicate that neuronal activity in the
amygdala and hippocampus is reduced in PD patients which
may speciﬁcally impact on olfactory sensitivity. In addition,
neuronal activity in components of corticostriatal loops
appearstobeupregulatedindicatingcompensatoryprocesses
involving the dopaminergic system.
3.OlfactoryDysfunctionas
aP r odr o m a lS ym p t o m
Support for the existence of a prodromal phase comes from
imaging, neuropathology, and various clinical or epidemi-
ological surveys. The best evidence that derives from large
prospectivestudiesrelatestodisordersaﬀectingolfaction,the
enteric nervous system, and depression [26–28]. Estimates
for the duration of the prodrome range from 2 to 50 years
depending on the symptom, duration of followup, accuracy
of diagnosis, and individual variation.
PD patients frequently report reduction in their sense
of smell that occurs a few years prior to the onset of
motor symptoms. However, patients’ unawareness of smell
deﬁcits may account for the inconsistent results described
in retrospective surveys. In a small study [29], upon ques-
tioning prior to olfactory testing, 9 out of 37 patients (24%)
indicated an awareness of a decrease of olfactory function
which actually preceded their diagnosis of PD.
A plethora of evidence from recent studies supports the
view that deﬁcits in the sense of smell may precede clinical
m o t o rs y m p t o m sb yy e a r s .As t u d yb yP o n s e ne ta l .[ 30]
on 361 asymptomatic relatives of PD patients selected 40
relatives with the lowest olfactory performance. Within 2
years of followup, 10% of these ﬁrst-degree relatives of PD
patients with signiﬁcant olfactory loss developed clinical PD.
In a followup study, ﬁve years from baseline testing [31],
ﬁve relatives had developed clinical PD as deﬁned by the
United Kingdom Parkinson’s Disease Society Brain Bank
Diagnostic Criteria for Parkinson’s Disease. Initial clinical
(motor) symptoms appeared 9 to 52 months (median 15
months) after baseline testing. Poorer performance on each
of three olfactory tasks was associated with an increased risk
of developing PD within 5 years. In 2007 [32], we published
data on a clinical followup of a previous investigation [33],
in which 30 patients diagnosed with idiopathic olfactory
loss participated. Four years from baseline, 7% (n = 2)
of the individuals with idiopathic olfactory loss who were
available for followup examination (n = 24) had newly
developed clinical PD symptoms. Altogether, 13% (n = 4)
of the patients presented with PD-relevant abnormalities of
the motor system. The results indicated that unexplained
olfactory loss may be associated with an increased risk of
developing PD-relevant motor symptoms.
This is in accord with the results of a large longitudinal
study by Ross and colleagues [34]. They assessed olfactory
functionin2267elderlymenintheHonoluluHeartProgram
and found an association between smell loss and future
development of PD. They came to the conclusion that
impaired olfaction can predate PD by at least 4 years and
may be a useful screening tool to detect those at high risk for
development of PD in later life. However, this relationship
appears to weaken beyond the 4-year period.
Along with quantitative smell loss, such as hyposmia,
idiopathic phantosmia has also been suggested to herald
PD. A number of case reports could show that some
patients have experienced phantosmia very early in the
course of the disease [35–37]. According to a recent study
by Landis et al. [38], however, idiopathic phantosmia as
an early sign of PD remains probably a rather exceptional
presentation whereas the overwhelming majority of people
with idiopathic phantosmia will not develop PD.
Recent data on olfactory loss as a PD symptom that is
present at the earliest stages of the disease are compatible
with predictions made on the basis of neuropathological
investigations. Braak et al. [39] describe involvement of
olfactory pathways and lower brainstem before nigrostriatal
pathways are aﬀected which might cause early nonmotor4 Parkinson’s Disease
symptoms. Huisman et al. [40] found an increase of
(inhibitory) dopaminergic neurons in the olfactory bulb
in PD patients. They interpreted their ﬁnding within the
context of a possible compensatory mechanism in response
to the loss of dopaminergic neurons in the basal ganglia.
This concurs with their observation that dopaminergic neu-
rogenesis in the glomerular layer tripled after nigrostriatal
lesioning and, consistent with this ﬁnding, the total number
of tyrosine hydroxylase- (TH-) positive cells increased [41].
However, results ofa followup study [42] indicated a gender-
related change,that is, thatthenumber ofdopaminergiccells
in the olfactory bulbs of both male and female Parkinson’s
patients equals that of healthy males of the same age
group. Authors, therefore, concluded that the hyposmia in
Parkinson’s disease patients cannot simply be ascribed to
dopamine in the olfactory bulb.
Regardless the small number of prospective studies in
this ﬁeld, olfactory loss should be considered a promising
contribution to the early diagnosis of PD. For instance,
the current Parkinson’s associated risk syndrome (PARS)
study [43] will advance our understanding of early PD
presentation.
4.OlfactioninDifferentialDiagnosis
Numerous studies suggest that olfactory disturbances in
PD may have diagnostic utility for the diﬀerentiation of
PD from other movement disorders. Wenning et al. [44]
presented data suggesting that olfactory function is dif-
ferentially impaired in distinct Parkinsonian syndromes.
They reported a preserved or mildly impaired olfactory
function to be more likely for atypical parkinsonism such
as multiple system atrophy, progressive supranuclear palsy,
or corticobasal degeneration whereas markedly pronounced
olfactorylossappearedtosuggestPD.Similartotheresultsof
Wenning et al., in a study on 50 Parkinsonian patients [29],
we also found evidence for olfactory loss in MSA, but little
or no olfactory loss in (the few investigated) patients with
PSP and CBD. With regard to the diﬀerentiation between
MSA and PD (Figure 3)a tac u t o ﬀ of a TDI score (combined
results for odor thresholds, odor discrimination, and odor
identiﬁcation; see also [15]) of 19.5, psychophysical testing
had a sensitivity of 78% and a speciﬁcity of 100%. When
the cutoﬀ TDI score was increased to 24.8, sensitivity in this
samplewas100%while speciﬁcityfell to63%.This moderate
speciﬁcity seems to be the limiting parameter for diagnostic
purposes. ArecentAmericanAcademyofNeurologypractice
parameter on the diagnosis and prognosis of PD concluded
that olfactory testing “should be considered” to diﬀerentiate
PD from PSP and CBD but not from MSA [45]. Further-
more, Liberini et al. [46] reported a signiﬁcant olfactory
impairment in Lewy body disease (LBD) which does not
allow diﬀerentiation from PD. In a sample of 116 patients
with mild LBD, mild Alzheimer’s disease, mild cognitive
impairment, and controls, Williams et al. [47]d e s c r i b ee v e n
more marked olfactory impairment in patients with mild
dementia with Lewy bodies than present in those with mild
Alzheimer’s disease. This lends signiﬁcance to the role of
Lewy body pathology in olfactory dysfunction [48]w h i c h
would be in line with the observation that patients with
nondegenerative causes of parkinsonism such as vascular
parkinsonism [49] present with preserved smell function.
There is also evidence for less olfactory disturbance in famil-
ial parkinsonism. In PARK2, the olfactory sense is relatively
well preserved whereas PARK1 subjects are mildly hyposmic.
Recent data [50] suggest that PARK 8 individuals present
with impaired olfactory identiﬁcation whilst asymptomatic
carriers show normal olfactory performance.
In secondary parkinsonism, study results also indicate a
relationship between Parkinsonian symptoms and olfactory
dysfunction. We found an association between medication-
induced parkinsonism and olfactory dysfunction in patients
with psychotic depression treated with D2-blocking neu-
roleptic drugs [51]. Here, the severity of motor symptoms
was positively correlated with the degree of olfactory dys-
function which might indicate patients with a latent basal
ganglia dysfunction. Similar to the results seen in drug-
induced parkinsonism, data from a recent study reveal that
Wilson’s disease patients with neurological symptoms show
a signiﬁcant olfactory dysfunction compared to hepatic-type
patients [52]. Individuals who are more severely neurolog-
ically aﬀected also present with more pronounced olfactory
deﬁcits.Based ontheseobservations, olfactorytesting should
not be considered to diﬀerentiate PD from these speciﬁc
conditions. However, olfactory testing has been shown to be
important in cases where patients present with Parkinsonian
features but with preserved olfaction. Here, it appears valid
to question a diagnosis of PD.
5.Conclusions
Recent data suggest that inexpensive olfactory probes
improve the diagnostic process in patients with PD. In
contrast to imaging procedures, olfactory testing is quick
and easy to perform. Validated tests can be used as reliable
diagnostic tools even in nonspecialized centers. Deeb et al.
[53]found thata basic smell test is as sensitive as a dopamine
transporter scan. According to this study, the sensitivities
of the University of Pennsylvania Smell Identiﬁcation Test
[54] and DaTSCAN are high at 86% and 92%, respectively.
Although DaTSCAN is superior for “localization,” a smell
test is considerably “cheaper,” and neither is disease speciﬁc.
Consequently, structured and validated tests of olfactory
function should be a mandatory part of the early and
diﬀerential diagnosis of PD.
Our experience suggests that it only takes little time
to follow up patients with a diagnosis of idiopathic smell
loss neurologically as an essential part of their regularly
scheduled visit to the Smell and Taste Clinic which is a
time- and expense-eﬃcient process well warranted. Such
a comprehensive multidisciplinary approach might enable
the physician to detect slight motor abnormalities in an
at-risk population as early as possible. This may also
give rise to clinical studies which allow administration of
neuroprotective substances in individuals with, for example,
unexplained smell loss. Up till now, therapeutic studies withParkinson’s Disease 5
neuroprotectiveagentsinhyposmicPDpatientsarecurrently
underway and may help us to evolve preventive strategies for
PD in future.
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